Latest osteosarcoma Stories
INDIANAPOLIS, July 23 /PRNewswire-FirstCall/ -- Today, Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration (FDA) has approved a new use for its osteoporosis drug FORTEO((R)) [teriparatide (rDNA origin) injection] to treat osteoporosis associated with sustained, systemic glucocorticoid therapy in men and women at high risk of fracture. Glucocorticoid therapy is the most common cause of secondary osteoporosis, leading to bone loss and an increased risk for...
SAN MARINO, Calif., June 22 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) stuns the medical and scientific communities with a dramatic demonstration of single-agent efficacy with its lead product, Rexin-G, for metastatic cancer. The landmark article (accessible online as of June 16, 2009 in Molecular Therapy, the Official Journal of The American Society of Gene Therapy, www.nature.com/mt/) documents the results of two related studies using Rexin-G, a tumor-targeted...
A grant from the Liddy Shriver Sarcoma Initiative will allow Dr. Pulivarthi Rao, associate professor of pediatrics at Baylor College of Medicine, and his team of researchers to explore the role of the gene CDC5L in the development of osteosarcoma, the most common bone cancer in children.Rao received the $50,000 one-year grant for his research proposal, "Molecular basis of genomic instability in osteosarcoma.""Osteosarcoma is often present with complex chromosomal rearrangements, deletions and...
SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies (www.epeiusbiotech.com) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial...
OSAKA, Japan, and IRVINE, Calif., May 18 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) and IDM Pharma, Inc. (Nasdaq: IDMI) today announced that Takeda America Holdings, Inc., a wholly-owned subsidiary of Takeda (Takeda America), and IDM Pharma have entered into an agreement for Takeda America to acquire IDM Pharma. Takeda America has established Jade Subsidiary Corporation as a wholly-owned subsidiary to effect that transaction. Under the agreement, Takeda...
HUNTSVILLE, Ala., May 5 /PRNewswire/ -- Osteosarcoma is the most common and potentially most dangerous bone cancer. It primarily affects young people between the ages of 10 - 25. In "Cancer from A to Z" (published by AuthorHouse), a new cancer dictionary by Dr. Edward Laughlin, learn that before the 1980's the only treatment for osteosarcoma was amputation. An oncologist's office can be an intimidating place to enter, and the terminology barrier does not make the feeling disappear. In Dr....
NEW YORK, April 29 /PRNewswire-USNewswire/ -- Blood fluoride levels were significantly higher in patients with osteosarcoma than in control groups, according to research published in Biological Trace Element Research (April 2009). Osteosarcoma, a rare bone cancer, occurs mostly in children and young adults. Randhu and colleagues measured serum fluoride levels in three equal groups of age-matched and sex-matched patients. Group one had osteosarcoma, group two had non-osteosarcoma bone...
First New Agent Approved to Treat Osteosarcoma in More Than 20 Years IRVINE, Calif., March 9 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that the European Commission has formally granted a Centralized marketing authorization for MEPACT(R) (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults. The Centralized marketing authorization...
IRVINE, Calif., Feb. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that it is joining the National Organization for Rare Disorders (NORD) and more than 100 patient organizations, caregivers, researchers and companies developing treatments for rare diseases to observe Rare Disease Day on February 28. The goal of the day is to bring attention to rare diseases, the challenges encountered by those affected and the importance of research to develop diagnostics...
SAN MARINO, Calif., Feb. 12 /PRNewswire/ -- Epeius Biotechnologies announces the launch of its new informative website, containing an award-winning video and an interactive e-book designed to introduce the general public to the tumor-targeting and cancer-destroying biotechnologies behind the clinical development of Rexin-G. Honored as the first and so far only targeted, genetic medicine that has been validated in clinical trials worldwide (Nature Reviews, Genetics, 2007), Rexin-G is...
